

euroPLX



Business Developer

Vol. 15 # 5 | May | 2019

## Company Mergers and Acquisitions Abound: Less Management Changes

\* Acquisition: **Aura Health Inc.** has closed the acquisition of an 80% equity interest in **Pharmadrug Production GmbH** for total consideration of €5.0 million in a move to enter the European market. 17 May 2019 ([www.aurahealthinc.com](http://www.aurahealthinc.com))

\* Name change: **Blake Insomnia Therapeutics, Inc.** has submitted a name change request to rebrand as **BioHemp International**. 15 May 2019 ([www.biohempinternational.com/](http://www.biohempinternational.com/))

\* Toll manufacture: **Cantargia AB** and **Patheon Biologics B.V.** (part of **ThermoFischer Scientific**) have signed an agreement regarding future production of the antibody CAN04 (nidanilimab). CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. 13 May 2019 ([cantargia.com](http://cantargia.com))

\* Acquisition: **Catalent, Inc.**, has completed the \$1.2 billion acquisition of **Paragon Bioservices, Inc.**, a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon's specialised expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalise on strong industry tailwinds in the potentially \$40 billion addressable

market for gene therapies. 20 May 2019 ([www.catalent.com](http://www.catalent.com))

\* Licensing and Distribution: **Cumberland Pharmaceuticals Inc.** has entered into an exclusive agreement with China's **Winhealth Pharma Group** for the licensing rights of Acetadote® (acetylcysteine) Injection, used to prevent or reduce liver damage resulting from acetaminophen overdose, and Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Winhealth licensing rights to commercialise both FDA approved drugs in China. 15 May 2019 ([www.cumberlandpharma.com](http://www.cumberlandpharma.com))

\* Acquisition: **Cure Pharmaceutical**, an innovative drug delivery and development company, has closed on the previously announced acquisition of **Chemistry Holdings Inc.**, a formulation technology company that is developing innovative delivery systems for a variety of industries. The acquisition was an all-stock transaction using common stock. In connection with the signing and closing of this acquisition, CURE received a total of \$10M in cash. 14 May 2019 ([www.curepharmaceutical.com](http://www.curepharmaceutical.com))

\* Name change: **Egalet Corporation** announced it will change its

name to **Zyla Life Sciences** in the coming weeks. The name change reflects an intention to shift the company's focus from an abuse-deterrent technology company to a broader commercial life sciences business committed to bringing important products to patients and healthcare providers. 16 May 2019 ([www.egalet.com](http://www.egalet.com))

\* Distribution: **Emerald Health Therapeutics, Inc.** has been authorised by **PEI Cannabis** and **Manitoba Liquor & Lotteries Corporation** to supply Emerald-branded cannabis products into those provinces. Emerald has also fulfilled its first shipments of premium cannabis products to PEI Cannabis and to licensed private retailers in Saskatchewan. 14 May 2019 ([emeraldhealth.ca/en](http://emeraldhealth.ca/en))

\* Acquisition: **EVER Pharma Holding Ges.m.b.H** (Austria) announced that it has completed the acquisition of **Amneal Deutschland GmbH**, a subsidiary of Amneal Pharmaceuticals that operates the company's commercial operations in Germany. The acquired entity will be rebranded to EVER Pharma GmbH. Financial terms were not disclosed. 17 May 2019 ([www.everpharma.com](http://www.everpharma.com))

\* Acquisition: **Evotec AG** signed a definitive agreement under

which Evotec will acquire **Just Biotherapeutics, Inc.**, for up to \$ 90 m including potential performance-based earn-out components expected within the next three years. Just Biotherapeutics is a unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for design, development, and manufacturing of biologics. 20 May 2019 ([www.evotec.com](http://www.evotec.com))

\* Acquisition: **Roche** and **Spark Therapeutics, Inc.** intend to refile on or about 23 May 2019 their respective Premerger Notification and Report Forms under the Hart-Scott-Rodino Act, in order to provide the U.S. government additional time to complete its review of the proposed \$4.8 billion transaction. 14 May 2019 ([www.roche.com](http://www.roche.com))

\* Acquisition: **H. Lundbeck A/S** and **Abide Therapeutics, Inc.** signed a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition pro-

vides Lundbeck a novel discovery platform and a U.S.-based research hub. 6 May 2019 ([www.lundbeck.com](http://www.lundbeck.com))

\* Distribution: **Lupin Limited** and **Aptissen S.A.** have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. 9 May 2019 ([www.lupin.com](http://www.lupin.com))

\* Spin off: **Nimble Therapeutics** has begun operating as a standalone business after spinning out from **F. Hoffmann La Roche** to commercialise its proprietary chemical synthesis technology for drug discovery and development. 30 Apr 2019 ([www.nimbletherapeutics.com](http://www.nimbletherapeutics.com))

\* Acquisition: **Novartis** has entered into an agreement with **Takeda Pharmaceutical Company Limited** to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide, a prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. Deal terms include a USD 3.4 billion upfront payment with potential milestone payments of up to USD 1.9 billion. As part of the agreement, Novartis will be taking on approximately 400 employees associated with the product. 9 May 2019 ([www.novartis.com](http://www.novartis.com))

\* Licensing: **Onconova Therapeutics, Inc.** has entered into a license agreement for the Greater China territory with **HanX Biopharmaceuticals, Inc.**, a China-based pharmaceutical company focused on the development, registration, and commercialisation of novel oncology products in China, to develop and commercialise rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment

of higher-risk MDS (HR-MDS). 13 May 2019 ([www.onconova.com](http://www.onconova.com))

\* New facility: **Pfizer Inc.** open a new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer's Andover site houses commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines. With its modular and flexible design, the newly opened Andover Clinical Manufacturing Facility (ACMF) will expand the capacity for Pfizer's BioTherapeutics Pharmaceutical Sciences organisation to manufacture clinical supplies. Pfizer's ACMF investment is over \$200 million and includes five independent manufacturing suites to advance Pfizer's robust pipeline of potential new biotherapeutics and vaccines, with more than 50 projects in development. 9 May 2019 ([www.pfizer.com](http://www.pfizer.com))

\* Acquisition: **Pfizer Inc.** has entered into a definitive agreement to acquire all the shares of **Therachon Holding AG**, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS). Under the terms of the agreement, Pfizer will acquire Therachon for \$340 million upfront with an additional \$470 million in additional payments contingent on the achievement of key milestones in the development and commercialisation of TA-46 for the treatment of achondroplasia, a genetic condition and the most common form of short-limbed dwarfism. 8 May 2019 ([www.pfizer.com](http://www.pfizer.com))

\* Divestiture: **Takeda Pharmaceutical Company Limited** has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product ("Xiidra®") to **Novartis** and its TachoSil® Fibrin Sealant Patch ("TachoSil®")

to **Ethicon** as part of its strategy to focus on core business areas. akeda will receive \$3.4 billion upfront in cash and up to an additional \$1.9 billion in potential milestone payments from Novartis, and approximately \$400 million upfront in cash from Ethicon. 8 May 2019 ([www.takeda.co.jp](http://www.takeda.co.jp))

## BD People on the Move

\* Accord Healthcare Ltd.: **Cerem Çavdar**, who has been Manager for Business Development and In-Licensing, EMENA, left the company. (Corp Comm 5 May 2019)

\* Biocon Ltd: **Yash Khosla**, until most recently Director of Business Development & Licensing at Lupin Europe Ltd. has been appointed as Regional Head of Europe & ANZ and is registered for euroPLX 70 Berlin. (Pers Comm 14 May 2019)

\* CytoDyn, Inc.: **Brendan Rae**, Ph.D., J.D., who comes from Serina Therapeutics where he was Chief Business Officer, responsible for partnering, out licensing and overall company strategy has been appointed as Senior Vice President of Business Development. (Press Release 14 May 2019)

\* Phytopharm KI ka S.A.: **Paula Lecka**, who has been Business Development Manager finished her employment for the company. (Corp Comm 6 May 2019)

## Newcomers to euroPLX 70 Berlin - part 2

More than 15% of the companies registered for euroPLX 70 Berlin are companies which have never attended any euroPLX event before. See part 2 of the list:

Located in Böblingen, Germany, **AAA-Pharma** ([www.aaa-pharma.de](http://www.aaa-pharma.de)) is part of the Woerwag group, representing its German generics business.

**Biose** ([www.biose.com](http://www.biose.com)) of

Clermont Ferrand, France, is an independent, family-owned pharmaceutical company focusing on microbiome medicine: discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products.

Based in Radomir, **Danhson-BG** ([www.danhson.bg](http://www.danhson.bg)) is a Bulgarian, privately owned holding company that develops, manufactures and markets branded generic products. The company is a part of an international group with business operations in Bulgaria, Russia, the CIS countries and South-East Asia.

Being part of the Group Medigray, **DR Pharma** is a privately owned pharmaceutical company manufacturer and marketer of generics products in Central America, Dominican Republic, and Peru, with offices in San José, Costa Rica. The company is based in San José, Costa Rica.

**Excella GmbH & Co. KG** is the German manufacturing site of Fareva, a Luxembourg based company focusing on research, manufacturing and packaging solutions for cosmetic, make-up, pharmaceutical, industrial and household products.

Located in Hohenlockstedt, Germany, **G. Pohl-Boskamp GmbH & Co. KG** ([www.pohl-boskamp.de](http://www.pohl-boskamp.de)) is one of Germany's leading mid-sized pharmaceutical companies focusing on cardiovascular, respiratory/ENT, urology and parasitology areas. The company exports its products to more than 40 countries.

Based in the town of Fisciano, Italy, **Genetic SpA** ([www.geneticspa.com](http://www.geneticspa.com)) is an R&D focused pharmaceutical company with a portfolio of prescription drugs, medical devices and dietary supplements in several therapeutic areas.

With headquarters in Esbjerg, Denmark, **Nordic Prime** ([nordicprime.dk](http://nordicprime.dk)) is a Danish parallel importer of quality medicine, buy-

ing from within the EU and selling to the Nordic countries, primarily Denmark and Sweden.

**Perffarma** ([www.perffarma.com](http://www.perffarma.com)) is a French company servicing the pharmaceutical industry in markets of Central Europe, Maghreb, Latam and East Africa.

With more than 165 products in anti-hypertensives, anti-diabetics, lipid-lowering, anti-infective, antibiotics, respiratory management, hematinics, anti-allergics, steroids, psychotropics, calcium and vitamin supplements and others, **Unison Pharmaceuticals Pvt Ltd** ([www.unisonpharmaceuticals.com](http://www.unisonpharmaceuticals.com)) of Ahmedabad, Gujarat, India, ranks among the top 40 companies of this country.

**V-Ensure Pharma Technologies Pvt. Ltd.** ([www.v-ensure.com](http://www.v-ensure.com)) of Mumbai, India is a contract research company based focusing on forms such as injectables, solid orals, and liquid oral suspensions.

**Veeda Clinical Research Pvt. Ltd.** ([www.veedacr.com](http://www.veedacr.com)) is an independent CRO based in Ahmedabad, India, offering a diverse range of clinical studies.

**Zinereo Pharma** is a newly established spin-off of the Spanish company Biofabri S.L. specialised in the development and manufacture pharmaceutical products and probiotics.

## The Interactive Hub for Business Development

euroPLX is the world's most often held partnering conference for the pharma and biopharma industries.

Because of results delivered. Year-round.

Join the 71st International Partnering Conference for Pharma Business Development\*

### \*euroPLX 71 Lisbon (Portugal)

November 25 + 26, 2019, Hotel Cascais Miragem, Cascais (near Lisbon)

euroPLX events are temporary interactive hubs for pharma business development. Running for several months on an online platform, they are complemented by personal meetings of the participating executives during a concluding two-days partnering conference.

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Register online: [www.europlx.com](http://www.europlx.com)

 **euroPLX**  
by RauCon

[www.europlx.com](http://www.europlx.com)  
[meetyou@europlx.com](mailto:meetyou@europlx.com)  
ph. ++49 (6221) 426296-0

The Original since 1995.  
Often copied. Never equaled.

